key: cord-0695706-hbzn8dqm
authors: Yang, Stephen Su; BPharm, Rosa Boudjemai; Lipes, Jed
title: Interleukin-6 antagonist Tocilizumab to treat critically ill COVID-19 patients with cytokine release syndrome – a case series
date: 2020-10-24
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2020.10.040
sha: 44d2206c2a546d05d55f39db00cf55b6c47f4800
doc_id: 695706
cord_uid: hbzn8dqm

nan

To the editor, Severe coronavirus disease 2019 (COVID-19) will often require admission to an intensive care unit (ICU). A possible etiology may be mediated by immune dysregulation leading to cytokine release syndrome (CRS). 1 Clinically, CRS results in fever, severe hypoxia and/or hemodynamic collapse for which IL-6 is one of the central cytokines involved. 2 Tocilizumab is a recombinant monoclonal antibody that binds specifically to IL-6 receptors, which may halt the cytokine storm and is a promising therapy to consider. We described a case series of 12 COVID-19 patients admitted to ICU who received Tocilizumab in the context of CRS. This study was approved by our local Institutional Review Board.

The median age was 66 years (interquartile range [IQR] 54-71; range 51-73), and 9 of 12 patients (75.0%) were male. The median sequential organ failure assessment score on admission was 8 (IQR 6-9) ( Table 1) . The most common dose (83.3%) of Tocilizumab was 8 mg/kg. The indications for therapy were hypoxia (58.3%), shock (16.7%), or both hypoxia and shock (25.0%) ( Table 2) . Hypoxia was defined as need for oxygen therapy more than 70% in an intubated patient. Shock was defined as need for high doses of vasopressors (i.e. norepinephrine ≥15 mcg/min). Eight patients (66.7%) improved clinically after 48 hours, defined as a decrease of at least 25% in F I O 2 requirement and/or a decrease of at least 25% in vasopressor dose. Four patients (33.3%) remained unchanged clinically. There was an increase in P a O2/F I O2 ratio over 5 days after Tocilizumab administration (Figure 1) , while a large decrease in C-reactive protein was seen over 5 days after Tocilizumab administration ( Figure 2 ). Ten patients (83.3%) were discharged from ICU and two patients were deceased (16.7%) ( Table 3) .

Currently, there is no proven therapy to treat critically ill COVID-19 patients other than supportive measures. 3 We found significant short-term clinical improvement with the use of Tocilizumab in our case series of patients with decrease in inflammatory markers, improved hemodynamics as well as oxygenation parameters. Many questions remain regarding how to best use this therapy in COVID-19, in particular the optimal dose and timing of therapy is largely unknown. Most patients with severe COVID-19 that require hospitalization will recover with supportive measures despite therapy with IL-6 blockade. 4 However, some studies have shown that early administration of Tocilizumab prior to ICU admission is associated with improved outcomes. 5 Patients who receive therapy only once acute respiratory distress syndrome (ARDS) develops may not benefit from IL-6 blockade. Thus, it will be important to select patients at the highest risk to deteriorate and progress to ARDS and CRS. In our series, patients received therapy a median of 5 days from ICU admission. Although we did note improved clinical outcomes in 66.7% of patients, perhaps it was already too late to mitigate the lung damage and improve mortality. Further studies will be required to determine optimal timing of therapy.

Our case series has important limitations. The small sample size and short-term follow-up limits interpreting our findings. All observations are hypothesis-generating and cannot be considered causal. Moreover, almost all patients received corticosteroids which may have confounded our findings.

IL-6 blockade may become an important strategy in critically ill COVID-19 patients however many questions remain. Selecting the right patient at the right time is likely going to be an Results expressed as n (%) unless otherwise stated.

AKI: acute kidney injury; ICU: intensive care unit; VAP: ventilator associated pneumonia ⁎ Defined as a decrease in at least 25% FIO2 requirement and/or a decrease in at least 25% vasopressor dose

Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care

Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab -A Case-Controlled Study

important challenge in order to balance potential risks and benefits. High-quality clinical studies will be required to determine the role, if any, in this emerging disease.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.